PILLAR-2: Diffuse Large B-Cell Lymphoma After Complete Remission With R-CHOP
PILLAR-2 (PIvotaLLymphoma triAls of RAD001) is a phase III, double-blind study of adjuvant everolimus therapy in poor-risk patients with diffuse large B-cell lymphoma who have achieved complete response to first-line R-chemotherapy.
Patients are randomized on a 1:1 ratio to receive continuous therapy with either everolimus (RAD001) 10 mg/day orally or placebo. This trial is enrolling approximately 915 patients with diffuse large B-cell lymphoma, at more than 220 sites worldwide. Poor risk is defined as an International Prognostic Index score of 3 to 5.
PILLAR-2 Key facts
Primary endpoint: Disease-free survival
Secondary endpoints:
Overall survival
Lymphoma-specific survival
Safety
Target enrollment: 915
*Treatment until disease progression, unacceptable toxicity, death, or discontinuation for any other reason.
Click here to learn more about this clinical trial and participating centers from ClinicalTrials.gov.
Disclaimer : These are investigational studies; there is no guarantee that everolimus will become commercially available for these indications
Disclaimer : This is a global web site for the The WIDE Program™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain program information that is different from where you practice. Please contact your local Novartis representative for the latest information specific to your country.
